Retatrutide, PCOS, and Fertility: Women's Health

Introduction

Polycystic ovary syndrome (PCOS) affects an estimated 8-13% of women of reproductive age and is the most common cause of anovulatory infertility. Central to PCOS pathophysiology is insulin resistance, which drives excess androgen production, disrupts ovulation, and contributes to metabolic complications including obesity, type 2 diabetes, and cardiovascular disease.

GLP-1 receptor agonists have attracted growing interest as potential treatments for PCOS due to their insulin-sensitizing effects and capacity for significant weight loss. Several studies with semaglutide and liraglutide have shown improvements in PCOS-related outcomes. As a triple receptor agonist with GLP-1, GIP, and glucagon receptor activity, retatrutide’s mechanism offers theoretical advantages for PCOS, but this is entirely extrapolation.

No retatrutide-specific PCOS data exist. There is no dedicated PCOS trial, no published subgroup analysis, and no preclinical PCOS model data for retatrutide. Everything discussed below regarding PCOS and fertility is based on GLP-1 class evidence, mechanistic reasoning, and the general relationship between weight loss and reproductive outcomes. Readers should interpret this content accordingly.

Why PCOS and GLP-1 Agonists Are Connected

Insulin Resistance as the Central Driver

Insulin resistance is present in approximately 70-80% of women with PCOS, regardless of body weight. Elevated insulin levels stimulate ovarian theca cells to produce excess androgens (testosterone, androstenedione), which suppress normal follicular development and prevent ovulation. Insulin resistance also reduces sex hormone-binding globulin (SHBG), increasing the fraction of free, biologically active androgens.

By improving insulin sensitivity, therapies that lower insulin levels can reduce androgen production, restore ovulatory cycles, and improve fertility. This is the rationale behind the established use of metformin in PCOS and the emerging interest in GLP-1 receptor agonists.

Weight Loss and PCOS

Weight loss is one of the most effective interventions for PCOS in women with overweight or obesity. Clinical data consistently show that:

• 5-10% weight loss can restore ovulatory menstrual cycles in a substantial proportion of women with PCOS
• Weight loss reduces circulating androgen levels and increases SHBG
• Weight loss improves insulin sensitivity independently of any pharmacological mechanism
• Even modest weight reduction improves fertility outcomes in women with PCOS

Retatrutide achieves 26-29% weight loss in Phase 3 (TRIUMPH-4 data, Eli Lilly press release, December 2025), far exceeding the 5-10% threshold that has been shown to improve PCOS outcomes in weight loss studies. However, the relationship between degree of weight loss and PCOS improvement is not necessarily linear, and the specific effects of very large weight reductions on PCOS have not been systematically studied.

GLP-1 Class Evidence in PCOS

Liraglutide

Liraglutide (Saxenda/Victoza) has been studied in several small trials in women with PCOS. Published data show improvements in menstrual regularity, reductions in circulating androgen levels, and improvements in insulin sensitivity markers. Some studies have demonstrated increased ovulation rates with liraglutide treatment.

Semaglutide

Semaglutide (Wegovy/Ozempic) has been evaluated in PCOS-related studies showing reductions in body weight, improvements in androgen profiles, and restoration of menstrual regularity in some participants. The larger weight loss achieved with semaglutide compared to liraglutide may translate into greater PCOS benefit, though head-to-head comparisons in PCOS populations are limited.

Limitations of Class Evidence

All GLP-1 agonist PCOS studies to date have been relatively small, short-term, and not powered for fertility or pregnancy outcomes. They establish biological plausibility and generate hypotheses, but do not provide the level of evidence required to recommend GLP-1 agonists as standard PCOS treatment. GLP-1 agonists are not currently approved for PCOS in any jurisdiction.

Theoretical Rationale for Retatrutide in PCOS

Enhanced Insulin Sensitization

Retatrutide’s dual incretin activity (GLP-1 + GIP receptor agonism) may provide enhanced insulin sensitization compared to GLP-1 receptor agonists alone. GIP receptor agonism has been associated with improved insulin sensitivity in adipose tissue, complementing GLP-1-mediated improvements in hepatic and peripheral insulin sensitivity. In women with PCOS, where insulin resistance is central to pathophysiology, this dual incretin effect could theoretically produce greater reductions in compensatory hyperinsulinemia and subsequently greater suppression of ovarian androgen production.

Magnitude of Weight Loss

The 26-29% weight loss achieved with retatrutide in Phase 3 is substantially greater than the 5-10% threshold associated with PCOS improvement. While it is plausible that this degree of weight loss would produce marked improvements in PCOS parameters, it is also possible that diminishing returns apply beyond a certain weight loss threshold, or that the speed of weight loss introduces its own physiological effects.

Glucagon Receptor Contribution

The glucagon receptor component of retatrutide’s mechanism has not been specifically evaluated in the context of PCOS. Glucagon receptor agonism primarily affects hepatic metabolism (fatty acid oxidation, glucose output). Any contribution to PCOS improvement would likely be indirect, through metabolic improvements rather than direct reproductive effects.

Important Caveat

All of the above is mechanistic reasoning and extrapolation. Without clinical data in PCOS populations, it is not possible to predict the magnitude, timing, or consistency of any PCOS-related benefit with retatrutide. Theoretical advantages based on mechanism do not always translate into clinical superiority.

Fertility Implications

Increased Fertility Through Weight Loss

One of the most important practical considerations for women of reproductive age using any GLP-1 receptor agonist is the potential for increased fertility. Significant weight loss and improved insulin sensitivity can restore ovulatory function in women who were previously anovulatory due to obesity or PCOS. This can occur before menstrual regularity is visibly restored, meaning that women may become fertile before they recognize the change.

This phenomenon has been widely discussed in the context of semaglutide and tirzepatide use. Anecdotal reports and emerging data describe unplanned pregnancies in women using GLP-1 agonists, often referred to informally as the “Ozempic babies” phenomenon. While systematic data are limited, the biological mechanism is well understood: weight loss and improved insulin sensitivity restore the hypothalamic-pituitary-ovarian axis function that was suppressed by obesity and hyperinsulinemia.

Retatrutide, with its larger weight loss effect, could theoretically produce even more pronounced restoration of ovulatory function, potentially leading to increased fertility. Women of reproductive age should be counseled about this possibility before starting any GLP-1 receptor agonist, including retatrutide if it receives approval.

Oral Contraceptive Absorption

GLP-1 receptor agonists delay gastric emptying as part of their mechanism of action. This delayed gastric emptying can theoretically reduce the rate and extent of absorption of oral medications, including oral contraceptive pills (OCPs). While dedicated pharmacokinetic studies have generally shown minimal impact on oral contraceptive levels with most GLP-1 agonists, the possibility of reduced absorption is a recognized class consideration.

For women relying on oral contraceptives for pregnancy prevention while using retatrutide or any GLP-1 receptor agonist, healthcare providers should discuss:

• The theoretical risk of reduced oral contraceptive absorption, particularly during dose escalation when gastrointestinal effects are most pronounced
• The potential benefit of non-oral contraceptive methods (IUD, implant, injection, patch, ring) that bypass gastrointestinal absorption entirely
• The need for reliable contraception given the potential for increased fertility from weight loss

This is a general class consideration, not a retatrutide-specific finding. No dedicated studies have evaluated retatrutide’s effect on oral contraceptive absorption.

Pregnancy and Retatrutide

Contraindication During Pregnancy

Retatrutide is an investigational drug, and its safety during pregnancy has not been established in humans. Based on GLP-1 receptor agonist class data, retatrutide would be expected to carry a pregnancy contraindication.

Animal reproduction studies for GLP-1 receptor agonists have shown adverse developmental effects, including embryofetal toxicity, in some species. Approved GLP-1 receptor agonists carry label warnings advising against use during pregnancy and recommending discontinuation at least two months before planned conception (the specific interval varies by product).

Women planning to become pregnant should discuss with their healthcare provider the appropriate timing for discontinuing any investigational or approved GLP-1 receptor agonist before attempting conception. This is critical because the drug and its metabolites need time to clear from the body after discontinuation.

No Human Pregnancy Data

There are no human pregnancy outcome data for retatrutide. Any risk assessment is based on GLP-1 class data and preclinical studies. Women who become pregnant while participating in retatrutide clinical trials would be expected to discontinue treatment immediately, and pregnancy outcomes would be tracked as part of trial safety monitoring.

Breastfeeding

No human data exist on whether retatrutide or its metabolites are excreted in breast milk. For approved GLP-1 receptor agonists, breastfeeding is generally not recommended due to the lack of human lactation data and the theoretical potential for adverse effects on the nursing infant. The same precautionary approach would be expected to apply to retatrutide.

Summary

Interest in retatrutide for PCOS and women’s reproductive health is driven by sound mechanistic reasoning: the drug’s insulin-sensitizing effects, substantial weight loss, and metabolic improvements address several core drivers of PCOS pathophysiology. GLP-1 class evidence from semaglutide and liraglutide studies supports the biological plausibility of benefit in PCOS.

However, no retatrutide-specific PCOS data exist. There is no dedicated PCOS trial, no published subgroup analysis, and no preclinical PCOS model data. All discussion of retatrutide and PCOS is extrapolation from class evidence and mechanistic reasoning.

For women of reproductive age, the most important practical considerations are: the potential for increased fertility through weight loss and improved insulin sensitivity, the need for reliable contraception (with consideration of non-oral methods), the contraindication during pregnancy based on GLP-1 class data, and the recommendation against breastfeeding in the absence of human safety data.

Frequently Asked Questions

Is retatrutide being studied for PCOS?

No. As of April 2026, there is no dedicated clinical trial evaluating retatrutide specifically for polycystic ovary syndrome. Any discussion of retatrutide and PCOS is based on GLP-1 class evidence and mechanistic extrapolation, not direct data.

Could retatrutide help with PCOS symptoms?

It is biologically plausible. Retatrutide improves insulin sensitivity and produces substantial weight loss, both of which are established interventions for PCOS. GLP-1 receptor agonists (semaglutide, liraglutide) have shown PCOS-related benefits in small studies. However, without retatrutide-specific PCOS data, any claim of benefit is speculative.

Can retatrutide increase fertility?

Significant weight loss and improved insulin sensitivity can restore ovulatory function in women who were previously anovulatory due to obesity or PCOS. This effect has been observed across the GLP-1 receptor agonist class and could theoretically be more pronounced with retatrutide given its larger weight loss effect. Women of reproductive age should be aware that fertility may increase and should use reliable contraception.

Does retatrutide affect birth control pills?

GLP-1 receptor agonists delay gastric emptying, which can theoretically reduce absorption of oral medications, including oral contraceptive pills. While dedicated studies for most GLP-1 agonists have shown minimal impact, healthcare providers may recommend non-oral contraceptive methods (IUD, implant, injection, patch, ring) to eliminate this concern entirely. No retatrutide-specific oral contraceptive interaction data exist.

Can I take retatrutide during pregnancy?

No. Retatrutide is investigational and not approved for any indication. Based on GLP-1 class data, which includes adverse findings in animal reproduction studies, use during pregnancy is contraindicated. Women should discontinue GLP-1 receptor agonists before attempting conception and consult their healthcare provider about appropriate timing.

Is it safe to breastfeed while using retatrutide?

There are no human data on retatrutide and breastfeeding. Based on the general approach for the GLP-1 receptor agonist class, breastfeeding is not recommended during treatment due to the lack of safety data. Women should discuss alternatives with their healthcare provider.